Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giovanni Battista Dell’isola has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Childhood absence epilepsy and developmental coordination disorder: an intriguing comorbidity

    by Maria Esposito, Rosangela Santomauro, Giovanni Battista Dell’ISola, Maria Ruberto, Giuseppe Di Cara, Alberto Verrotti, Marco Carotenuto

  • Clinical, etiological, and therapeutic profile of early-onset absence seizures: A case series analysis

    by Patrizia Bergonzini, Elisa Caramaschi, Alessandra Spallino, Giovanni Battista Dell'ISola, Elisabetta Spezia, Alberto Verrotti, Lorenzo Iughetti


  • Open Access

    Correction to: CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy

    by Giovanni Battista Dell’iSola, Antonella Fattorusso, Francesco Pisani, Mario Mastrangelo, Duccio Maria Cordelli, Piero Pavone, Pasquale Parisi, Alessandro Ferretti, Francesca Felicia Operto, Maurizio Elia, et al.


  • Open Access

    CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy

    by Giovanni Battista Dell'Isola, Fattorusso Antonella, Pisani Francesco, Mastrangelo Mario, Duccio Maria Cordelli, Pavone Piero, Parisi Pasquale, Ferretti Alessandro, Francesca Felicia Operto, Elia Maurizio, et al.

    CDKL5 deficiency disorder (CDD) is a complex clinical condition resulting from non-functional or absent CDKL5 protein, a serine–threonine kinase pivotal for neural maturation and synaptogenesis. The disorder manifests primarily as developmental epileptic encephalopathy, with associated neurological phenotypes, such as hypotonia, movement disorders, visual impairment, and gastrointestinal issues. Its prevalence is estimated at 1 in 40,000–60,000 live births, and it is more prevalent in females due to the lethality of germline mutations in males during fetal development. This Italian multi-center observational study focused on 34 patients with CDKL5-related epileptic encephalopathy, aiming to enhance the understanding of the clinical and molecular aspects of CDD. The study, conducted across 14 pediatric neurology tertiary care centers in Italy, covered various aspects, including phenotypic presentations, seizure types, EEG patterns, treatments, neuroimaging findings, severity of psychomotor delay, and variant-phenotype correlations. The results highlighted the heterogeneity of seizure patterns, with hypermotor-tonic-spasms sequence seizures (HTSS) noted in 17.6% of patients. The study revealed a lack of clear genotype–phenotype correlation within the cohort. The presence of HTSS or HTSS-like at onset resulted a negative prognostic factor for the presence of daily seizures at long-term follow-up in CDD patients. Despite extensive polypharmacotherapy, including medications such as valproic acid, clobazam, cannabidiol, and others, sustained seizure freedom proved elusive, affirming the inherent drug-resistant nature of CDD. The findings underscored the need for further research to explore response rates to different treatments and the potential role of non-pharmacological interventions in managing this challenging disorder.


  • Open Access

    The Effectiveness of Glycopyrronium in Drooling Managment: A Scoping Review Protocol

    by Giovanni Battista Dell’isola, Antonella De Lillo, Martina Giorgia Perinelli, Valeria Ottaviani, Pasquale Striano, Alberto Verrotti

    The management of pediatric drooling presents challenges requiring tailored therapeutic approaches. This scoping review examines the efficacy and safety of glycopyrronium in addressing drooling across diverse pediatric populations. Glycopyrronium, an anticholinergic medication, inhibits salivary gland activity, offering promise in managing drooling. Clinical trials and observational studies consistently demonstrate its effectiveness, particularly in children with neurological disabilities like cerebral palsy. Notably, glycopyrronium exhibits efficacy even at lower dosages, emphasizing personalized treatment. However, potential side effects such as dry mouth and vision changes necessitate careful monitoring. Future research should explore predictors of treatment response and include diverse patient populations to optimize management strategies. Overall, glycopyrronium emerges as a valuable therapeutic option for pediatric drooling, improving quality of life for affected children. This review underscores the importance of tailored approaches and highlights the need for further research to enhance outcomes in pediatric drooling management.


  • Open Access

    Current Overview of CDKL-5 Deficiency Disorder Treatment

    by Giovanni Battista Dell’isola, Katherin Elizabeth Portwood, Kirsten Consing, Antonella Fattorusso, Arnaldo Bartocci, Pietro Ferrara, Giuseppe Di Cara, Alberto Verrotti, Mauro Lodolo

    CDKL5 deficiency disorder (CDD) is a complex of clinical symptoms resulting from the presence of non-functional or absent CDKL5 protein, a serine–threonine kinase involved in neural maturation and synaptogenesis


  • Open Access

    Clinical spectrum and currently available treatment of type I interferonopathy Aicardi–Goutières syndrome

    by Giovanni Battista Dell’iSola, Gianluca Dini, Kaleb Logan Culpepper, Katherin Elizabeth Portwood, Pietro Ferrara, Giuseppe Di Cara, Alberto Verrotti, Mauro Lodolo

    Background: Aicardi–Goutières syndrome (AGS) is a genetically determined disorder with a variable phenotype. Since the original description of AGS, advances in gene sequencing techniques have resulted in a significant broadening of the phenotypic spectrum associated with AGS genes, and new clinical pictures have emerged beyond the classic presentation. The aim of this review is to provide a comprehensive analysis of the clinical spectrum of AGS and report currently available treatments and new immunosuppressive strategies. Data sources: Literature reviews and original research articles were collected from databases, including PubMed and ClinicalTrials.gov. Relevant articles about AGS were included. Results: The involvement of the nervous system certainly represents the major cause of mortality and morbidity in AGS patients. However, other clinical manifestations, such as chilblains, hepatosplenomegaly, and hematological disturbances, may lead to the diagnosis and considerably impact the prognosis and overall quality of life of these patients. Therapeutic approaches of AGS are limited to interventions aimed at specific symptoms and the management of multiple comorbidities. However, advances in understanding the pathogenesis of AGS could open new and more effective therapies. Conclusions: The over-activation of innate immunity due to upregulated interferon production plays a critical role in AGS, leading to multi-organ damage with the main involvement of the central nervous system. To date, there is no specific and effective treatment for AGS. New drugs specifically targeting the interferon pathway may bring new hope to AGS patients.


  • Clinical and electroencephalographic features of epilepsy in patients with triple X syndrome: A case series

    by Giovanni Battista Dell'ISola, Elisabetta Mencaroni, Paolo Prontera, Giuseppe Di Cara, Luigi Ferraro, Paolo Bonanni, Marco Carotenuto, Giulia Iapadre, Sara Matricardi, Francesca Operto, et al.


  • Open Access

    Expanding the genetic and clinical characteristics of Protocadherin 19 gene mutations

    by Giovanni Battista Dell’iSola, Elisabetta Mencaroni, Antonella Fattorusso, Giorgia Tascini, Paolo Prontera, Valentina Imperatore, Giuseppe Di Cara, Pasquale Striano, Alberto Verrotti

    Background: PCDH19-related epilepsy is a rare X-linked type of epilepsy caused by genomic variants of the Protocadherin 19 (PCDH19) gene. The clinical characteristics of PCDH19-related epilepsy are epileptic and non-epileptic symptoms with highly variable severity among patients. Case presentation: We present a case of a 4-year old female with PCDH19-related epilepsycaused by new variants in the PCDH19 gene. Our patient was admitted for the first time at the age of 12 months for seizure clusters arising under condition of apyrexia. The electroencephalography (EEG) showed frontal paroxysmal activity. The genetic analysis identified the two variants c.1006G > A (p.Val336Met) and c.1014C > A (p.Asp338Glu) in the gene PCDH19. The patient was treated with Carbamazepine and Clonazepam achieving the disappearance of seizures. During the follow-up, the neurological examination was persistently normal with neither cognitive impairment nor behavior disturbances. From 2 years of age EEG controls were persistently normal. Conclusion: This patient presents two novel variants of the PCDH19 gene associated with a mild form of epilepsy with normal cognitive development with an apparently better prognosis. According to our experience, the dual therapy with Carbamazepine and Clonazepam has led to a good control of seizures.


  • Open Access

    The Broad Clinical Spectrum of Epilepsies Associated With Protocadherin 19 Gene Mutation

    by Giovanni Battista Dell'ISola, Valerio Vinti, Antonella Fattorusso, Giorgia Tascini, Elisabetta Mencaroni, Giuseppe Di Cara, Pasquale Striano, Alberto Verrotti

    Protocadherin 19 (PCDH19) gene is one of the most common genes involved in epilepsy syndromes. According to literature data PCDH19 is among the 6 genes most involved in genetic epilepsies. PCDH19 is located on chromosome Xq22.1 and is involved in neuronal connections and signal transduction. The most frequent clinical expression of PCDH19 mutation is epilepsy and mental retardation limited to female (EFMR) characterized by epileptic and non-epileptic symptoms affecting mainly females. However, the phenotypic spectrum of these mutations is considerably variable from genetic epilepsy with febrile seizure plus to epileptic encephalopathies. The peculiar exclusive involvement of females seems to be caused by a cellular interference in heterozygosity, however, affected mosaic-males have been reported. Seizure types range from focal seizure to generalized tonic-clonic, tonic, atonic, absences, and myoclonic jerks. Treatment of PCDH19-related epilepsy is limited by drug resistance and by the absence of specific treatment indications. However, seizures become less severe with adolescence and some patients may even become seizure-free. Non-epileptic symptoms represent the main disabilities of adult patients with PCDH19 mutation. This review aims to analyze the highly variable phenotypic expression of PCDH19 gene mutation associated with epilepsy.